Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2012 Earnings Results

Alnylam Pharmaceuticals Beats on EPS, Stock Down 2.3%

Alnylam Pharmaceuticals reported a narrower-than-expected loss per share, which was a positive surprise for investors. However, the stock fell by 2.3% in reaction, likely due to the lack of revenue information and no guidance for the future. Investors may be concerned about the company's ability to navigate current market challenges without clear direction.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-1.20	N/A	+29.58%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed caution regarding market conditions. They reiterated their commitment to long-term strategies while acknowledging short-term difficulties.

Management highlighted ongoing challenges in the market.

They emphasized a focus on long-term growth despite current setbacks.

Alnylam Pharmaceuticals Beats on EPS, Stock Down 2.3%

Key numbers

Management commentary

Alnylam Pharmaceuticals, Inc.

More earnings this week

Alnylam Pharmaceuticals Beats on EPS, Stock Down 2.3%

Key numbers

Management commentary